Atai life sciences launches tryptagenix to further expand atai's robust intellectual property portfolio and strengthen atai's supply chain

Tryptagenix, a majority-owned joint venture with cb therapeutics, employs bioprospecting to develop new chemical entities with potential applications in mental health.

ATAI Ratings Summary

ATAI Quant Ranking